OUTCOME OF GPLLB/LLLA INHIBITORS IN TOTALLY OCCLUDED CORONARY ARTERY IN PATIENTS PRESENTING WITH ACUTE MYOCARDIAL INFARCTION LATE FOR THROMBOLYSIS OR PRIMARY PERCUTANEOUS CORONARY INTERVENTION
DOI:
https://doi.org/10.55519/JAMC-04-14013Keywords:
Acute myocardial infarction, GP IIb/IIIa inhibitors, Thrombolysis, Primary percutaneous coronary intervention, Renal Complication.Abstract
Background: Acute coronary ischemia is one of the most fatal cardiovascular events, presenting with tremendously high morbidity and mortality, especially in cases involving a completely occluded artery, leading to acute myocardial infarction (AMI). The study aimed to ascertain the efficacy and safety of glycoprotein IIb/IIIa (GP IIb/IIIa) inhibitors in Pakistani patients who present late for thrombolysis or primary percutaneous coronary intervention (PCI). Method: The trial was conducted at a tertiary care hospital in Islamabad, including 200 patients, with GP IIb/IIIa inhibitors used in 40% of infarct-related artery (IRA) cases. Results: The analysis revealed that GP IIb/IIIa inhibitors reduced major adverse cardiac events (MACE) by 9%, recurrent myocardial infarction (MI) by 7.5%, and improved thrombus resolution by 25%, as well as myocardial salvage by 12%. However, there was a higher rate of bleeding complications (p < .05) associated with their use. No other significant adverse events, such as in-hospital mortality, length of stay, or renal complications, were identified. Conclusions: These results suggest that GP IIb/IIIa inhibitors should not be used as a one-size-fits-all therapy. Proper patient selection, along with robust monitoring under dose-adjusted Eptifibatide or Tirofiban infusion regimens to target coagulation levels appropriately, is crucial. Although this treatment could be valuable in managing AMI, particularly in regions where advanced cardiac care is less accessible, further large-scale, multicenter studies are needed to determine its long-term safety and efficacy. This study provides a framework for further investigations into the use of GP IIb/IIIa inhibitors in similar patient populations.
References
1. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction—executive summary. Circulation. 2004;110(5):588-636.
2. Niccoli G, Scalone G, Lerman A, Crea F. Coronary microvascular obstruction in acute myocardial infarction. Eur Heart J. 2009;30(24):2886-93.
3. Topol EJ, Moliterno DJ, Herrmann HC, Powers ER, Grines CL, Cohen DJ, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med. 2001;344(25):1888-94
4. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994;330(14):956-61.
5. The PURSUIT Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med. 1998;339(7):436-43.
6. De Luca G, Suryapranata H, Stone GW, Antoniucci D, Tcheng JE, Neumann FJ, et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA. 2009;301(13):1365-73.
7. The TARGET Investigators. Comparison of abciximab and tirofiban for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med. 2001;344(25):1888-94.
8. Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, et al. Comparison of angioplasty with stenting with and without abciximab for acute myocardial infarction. N Engl J Med. 2001;344(7):493-501.
9. Henriques JP, Zijlstra F, van 't Hof AW, de Boer MJ, Dambrink JH, Gosselink AT, et al. Angiographic no-reflow phenomenon in acute myocardial infarction: the TIMI frame count and myocardial blush grade identify different forms of distal embolization. J Am Coll Cardiol. 2003;42(11):1772-7.
10. Zeymer U, Vogt A, Zahn R, Weber M, Tebbe U, Gottwik M, et al. Predictors of no reflow after primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction. Int J Cardiol. 2003;90(1):119-25.
11. Gershlick AH, More R, Banning AP, Dissanayake A, Rickards A, et al. A randomized, placebo-controlled trial of rescue angioplasty after failed thrombolysis: The Middlesbrough Early Revascularisation to Limit Infarction (MERLIN) trial. J Am Coll Cardiol. 2005;46(6):827-36.
12. Jolly SS, Yusuf S, Cairns J, Meeks B, Pogue J, Rokoss MJ, et al. Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomized, parallel group, multicentre trial. Lancet. 2009;377(9775):1409-20.
13. Tamhane UU, Gurm HS. The chimeric monoclonal antibody abciximab: a systematic review of its safety in contemporary practice. Expert Opin Drug Saf. 2008;7(6):809-19.
14. Dunn CJ, Foster RH. Abciximab: a pharmacoeconomic review of its use in percutaneous coronary revascularisation. Pharmacoeconomics. 1999;16:711-41.
15. O'Connor CM, Platek AE, McCullough PA. Safety profile of GP IIb/IIIa inhibitors: a review. Circulation. 2003;107(23):2924-9.
16. Stone GW, McLaurin BT, Cox DA. The safety and efficacy of GP IIb/IIIa inhibitors: a comprehensive review. N Engl J Med. 2004;350(24):2470-9.
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Fahad Khalid, Muhammad Fareed Khan, Wahab Anwar, Muhammad Fasihullah Khan, Muhammad Hasnain Iqbal, Naveed Yaqoob
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Journal of Ayub Medical College, Abbottabad is an OPEN ACCESS JOURNAL which means that all content is FREELY available without charge to all users whether registered with the journal or not. The work published by J Ayub Med Coll Abbottabad is licensed and distributed under the creative commons License CC BY ND Attribution-NoDerivs. Material printed in this journal is OPEN to access, and are FREE for use in academic and research work with proper citation. J Ayub Med Coll Abbottabad accepts only original material for publication with the understanding that except for abstracts, no part of the data has been published or will be submitted for publication elsewhere before appearing in J Ayub Med Coll Abbottabad. The Editorial Board of J Ayub Med Coll Abbottabad makes every effort to ensure the accuracy and authenticity of material printed in J Ayub Med Coll Abbottabad. However, conclusions and statements expressed are views of the authors and do not reflect the opinion/policy of J Ayub Med Coll Abbottabad or the Editorial Board.
USERS are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.
AUTHORS retain the rights of free downloading/unlimited e-print of full text and sharing/disseminating the article without any restriction, by any means including twitter, scholarly collaboration networks such as ResearchGate, Academia.eu, and social media sites such as Twitter, LinkedIn, Google Scholar and any other professional or academic networking site.
